Comparison of Two Methods and Three End Points in Determination of In Vitro Activity of Micafungin against Aspergillus spp
Open Access
- 1 August 2003
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (8) , 2640-2643
- https://doi.org/10.1128/aac.47.8.2640-2643.2003
Abstract
We investigated the in vitro activity of micafungin against clinical Aspergillus isolates ( n = 37) ( Aspergillusfumigatus [ n = 21], Aspergillusflavus [ n = 14], and Aspergillus niger [ n = 2]) by using NCCLS M38A microdilution and an investigational disk diffusion assay. Microdilution assay results were evaluated by using the end points of a MIC-2 (measured in micrograms per milliliter) and minimum effective concentration (MEC, measured in micrograms per milliliter; the lowest concentration of micafungin that produces short and aberrant hyphal branchings microscopically). Disk diffusion results were interpreted by measuring the zone(s) of inhibition (ZOI, measured in millimeters). Micafungin proved to be similarly active against all Aspergillus species tested. At 24 h, MIC-2s and MECs were identical. At 48 h, however, MIC-2s increased unpredictably, leading to the loss of a consistent correlation between the two end points. MECs and ZOI remained consistent and correlated at both reading times, suggesting their use as relevant end points in susceptibility testing of micafungin against Aspergillus . All Aspergillus isolates yielded intrazonal growth on disk diffusion agar plates. The intrazonal colonies contained short, aberrant hyphal branchings microscopically. The in vivo significance of these findings remains to be further investigated.Keywords
This publication has 15 references indexed in Scilit:
- Comparative Evaluation of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin against Aspergillus and Fusarium IsolatesAntimicrobial Agents and Chemotherapy, 2002
- New agents for the treatment of systemic fungal infections – current statusEmerging Drugs, 2002
- Echinocandins - an updateExpert Opinion on Therapeutic Patents, 2002
- In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium sppAntimicrobial Agents and Chemotherapy, 2002
- Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 against Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2001
- Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitorsExpert Opinion on Investigational Drugs, 2001
- In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium IsolatesAntimicrobial Agents and Chemotherapy, 2001
- Efficacy of FK463, a (1,3)-β- d -Glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida albicans Infection in MiceAntimicrobial Agents and Chemotherapy, 2000
- New targets and delivery systems for antifungal therapyMedical Mycology, 2000
- Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthaseAntimicrobial Agents and Chemotherapy, 1994